Zogenix, Inc. (ZGNX) reported fourth quarter EPS of ($0.13) in the extended session Tuesday, compared to the consensus estimate of ($0.13). Revenues increased 50.5% from last year to $14.9 million. Analysts expected revenues of $12.76 million. Net product revenue was $5.0 million, compared to $9.0 million in the fourth quarter 2013.
For the full-year 2014, the company reported total revenues of $40.5 million, up 23% from $33.0 million in the full year 2013. Net product revenue came in at $21.7 million, compared to $31.7 million yoy.
Separately, Zogenix today announced an agreement to sell Zohydro(R) ER Business to Pernix for $100 million plus regulatory and sales milestones up to $283.5 million.
On valuation measures, Zogenix Inc. shares, which currently have an average 3-month trading volume of 3.37 million shares, trade at a P/E to growth ratio of (0.12). The median Wall Street price target on the name is $2.50 with a high target of $3.50. Currently ticker boasts 4 ‘Buy’ endorsements, compared to no ’Holds’ and no ‘Sell’.
Profitability-wise, ZGNX has a t-12 profit and operating margin of (18.31%) and (243.67%), respectively. The $255.58 million market cap company reported $42.2 million in cash in its most recent quarter.
ZGNX currently prints a one year loss of about 57.67% and a year-to-date return of around 24.82%.
The chart below shows where the equity has traded over the last 52 weeks.
Zogenix Inc. is a pharmaceutical company, developing therapies that address specific clinical needs for people living with CNS disorders. The firm was founded in 2006 and is headquartered in San Diego, California.